A large body of evidence suggests that Akkermansia muciniphila may help protect against specific metabolic disorders and cardiometabolic risk factors associated with a low-grade inflammatory status.
To move from preclinical to clinical studies, Akkermansia muciniphila needed to be cultured in large amounts. A stable form was needed, at a quality level suitable for human use. However, the first culture medium used to grow Akkermansia muciniphila contained an animal-derived compound which was not compatible with human use. To overcome this issue, a synthetic medium was developed. This medium was devoid of incompatible compounds and enabled the culture of...